Article

Anees B. Chagpar Explains the Impact of Lifestyle Changes on Reducing Breast Cancer Risk

Oncologist Anees B. Chagpar sums up the various studies that have looked at lifestyle changes and cancer risk.

Anees B. Chagpar, director of the Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital in Connecticut, sums up the various studies that have looked at lifestyle changes and cancer risk.

"When we look at the impact of diet and exercise and obesity, different studies have different numbers in terms of the impact that can have on reducing risk, but we estimate that it's at least 10 percent," she says.

"If you think about that... breast cancer is the leading malignancy in women in this country and if we can reduce that by 10 percent by simply following fairly easy guidelines in terms of eating healthy, exercising and reducing our alcohol intake, we can have a significant impact in terms of population health."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content